FDA expands access to pancreatic cancer drug helping patients like Ben Sasse

The Food and Drug Administration has announced that it will allow certain pancreatic cancer patients to access a promising drug, daraxonrasib, even before it is officially approved for use. This medication, available in a 300 milligram pill taken once a day, works by blocking a signal that causes cancer cells to grow uncontrollably. According to drugmaker Revolution Medicine, clinical trials have shown that metastatic pancreatic cancer patients who took daraxonrasib survived a median of 13 months, compared to approximately six months for those who underwent chemotherapy.

Former Senator Ben Sasse, 54, who was diagnosed with stage-four pancreatic cancer in December, described daraxonrasib as a “miracle drug” in a recent interview with “60 Minutes.” He shared that the drug has helped him live longer and with less pain, reporting a significant reduction in tumor volume and pain levels since starting treatment.

The FDA has approved the use of daraxonrasib under its expanded access program, also known as compassionate use. This program allows patients with serious or terminal conditions to receive investigational therapies outside of a clinical trial. Eligible patients with previously treated metastatic pancreatic ductal adenocarcinoma who have exhausted all other options will now have the opportunity to receive daraxonrasib.

Revolution Medicine submitted the request for expanded access to daraxonrasib on April 28, and the FDA swiftly approved the protocol on April 30. FDA commissioner Marty Makary emphasized the agency’s commitment to facilitating early access to therapies for serious and life-threatening conditions like pancreatic cancer, with the hope of improving the lives of patients battling this disease.

Pancreatic cancer remains a significant health concern, with the National Cancer Institute predicting 67,530 new cases and 52,740 deaths in 2026. Despite accounting for only 3.2% of new cancer cases, pancreatic cancer is responsible for 8.4% of cancer-related deaths. The disease has a five-year survival rate of approximately 13.7%, though individual prognosis and treatment options can impact this statistic.

As research and advancements in cancer treatment continue to evolve, the FDA’s decision to grant early access to daraxonrasib represents a significant step forward in the fight against pancreatic cancer. With hope for improved outcomes and quality of life for patients, this innovative drug offers a beacon of light in the battle against this challenging disease.